Why is Glaxosmi. Pharma falling/rising?

As of 20-Aug, Glaxosmithkline Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 2,785.40, which represents a decrease of 24.55 points or 0.87%. The stock has underperformed its sector today by 0.45% and has shown a trend reversal after four consecutive days of gains. Over the past week, the stock has increased by 0.66%, but it has seen a significant decline of 10.90% over the past month. Despite a year-to-date increase of 23.98%, the stock has underperformed over the last year with a decrease of 3.84%. The stock's moving averages indicate it is higher than the 5-day and 200-day averages but lower than the 20-day, 50-day, and 100-day averages. Additionally, there has been a notable decrease in investor participation, with delivery volume falling by 13.92% against the 5-day average.
In the broader market context, the Sensex has increased by 1.64% over the past week, highlighting that Glaxosmithkline Pharmaceuticals Ltd is lagging behind the benchmark. While the company boasts high management efficiency with a return on equity of 42.32% and a low debt-to-equity ratio, these positive factors have not been sufficient to counterbalance the recent price decline. The majority ownership by promoters may provide stability, but the current liquidity situation, with a delivery volume of 75.91k, suggests a cautious sentiment among investors. Overall, the combination of recent price movements, underperformance relative to the sector, and declining investor participation contributes to the stock's current downward trajectory.